Relay Therapeutics Inc Quick Ratio (RLAY) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Relay Therapeutics Inc   (NASDAQ: RLAY)

Relay Therapeutics Inc 's Quick Ratio

RLAY's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 2.1 below Relay Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 13 other companies have achieved higher Quick Ratio than Relay Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 215, from total ranking in the second quarter 2026 at 482.

Explain Quick Ratio?
How much Cash & cash equivalents RLAY´s has?
What are RLAY´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RLAY/financial-strength
https://api.csimarket.com/api/v1/companies/RLAY/fundamentals
https://api.csimarket.com/api/v1/companies/RLAY/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
RLAY Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 81.43 %
Y / Y Cash & cash equivalent Change 35.63 %
Quick Ratio MRQ 2.1
RLAY's Total Ranking # 215
Seq. Current Liabilities Change 16.44 %
Seq. Cash & cash equivalent Change -86.37 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 14
Healthcare Sector # 71
Overall Market # 215


Quick Ratio Statistics
High Average Low
72.46 11.71 2.04
(Mar 31 2022)   (Jun 30 2023)




Financial Statements
Relay Therapeutics Inc 's Current Liabilities $ 59 Millions Visit RLAY's Balance sheet
Relay Therapeutics Inc 's Cash & cash equivalent $ 124 Millions Visit RLAY's Balance sheet
Source of RLAY's Sales Visit RLAY's Sales by Geography


Cumulative Relay Therapeutics Inc 's Quick Ratio

RLAY's Quick Ratio for the trailling 12 Months

RLAY Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 8.09 %
Y / Y Cash & cash equivalent TTM Growth 212.69 %
Quick Ratio TTM 8.01
Total Ranking TTM # 376
Seq. Current Liabilities TTM Growth 19.14 %
Seq. Cash & cash equivalent TTM Growth 2.53 %

Quick ratio ranking by company, industry and sector >> Back to RLAY Financial Strength Comparisons >> Go to Compare RLAY Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $59.15 millions, cumulative Quick Ratio decreased to 8.01 above the RLAY average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 139 other companies have achieved higher Quick Ratio than Relay Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2927 to 3437.

Explain Quick Ratio?
How much Cash & cash equivalents RLAY´s has?
What are RLAY´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 140
Healthcare Sector # 869
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
24.19 6.85 2.38
(Mar 31 2021)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Replimune Group Inc   5.57 $ 307.833  Millions$ 55.271  Millions
Denali Therapeutics Inc   5.42 $ 516.196  Millions$ 95.258  Millions
In8bio Inc   5.32 $ 13.973  Millions$ 2.628  Millions
Scholar Rock Holding Corp  5.16 $ 413.599  Millions$ 80.124  Millions
Revolution Medicines Inc   4.81 $ 3,651.385  Millions$ 758.773  Millions
Prokidney Corp   4.72 $ 141.864  Millions$ 30.038  Millions
Caribou Biosciences Inc   4.71 $ 94.881  Millions$ 20.144  Millions
Recursion Pharmaceuticals Inc   4.47 $ 549.853  Millions$ 122.918  Millions
Lineage Cell Therapeutics Inc   4.42 $ 45.199  Millions$ 10.217  Millions
Ginkgo Bioworks Holdings Inc   4.33 $ 285.361  Millions$ 65.849  Millions
Fate Therapeutics Inc   4.26 $ 139.132  Millions$ 32.691  Millions
Kymera Therapeutics Inc   4.16 $ 373.374  Millions$ 89.723  Millions
Monte Rosa Therapeutics Inc   4.16 $ 577.726  Millions$ 139.022  Millions
Vir Biotechnology Inc   4.08 $ 454.635  Millions$ 111.332  Millions
Moderna Inc   3.93 $ 7,976.000  Millions$ 2,028.000  Millions
Immunocore Holdings Plc  3.93 $ 901.298  Millions$ 229.619  Millions
Alector Inc   3.92 $ 138.697  Millions$ 35.415  Millions
Dbv Technologies S a   3.89 $ 165.700  Millions$ 42.600  Millions
Regenxbio Inc   3.71 $ 250.976  Millions$ 67.684  Millions
Tenaya Therapeutics Inc   3.55 $ 66.797  Millions$ 18.804  Millions
Alpha Cognition Inc.  3.41 $ 37.802  Millions$ 11.093  Millions
Intensity Therapeutics Inc   3.29 $ 8.494  Millions$ 2.582  Millions
Vivosim Labs Inc   3.19 $ 8.564  Millions$ 2.682  Millions
Adaptive Biotechnologies Corporation  3.02 $ 298.954  Millions$ 98.967  Millions
Atyr Pharma Inc   2.96 $ 48.751  Millions$ 16.463  Millions
Precision Biosciences Inc  2.90 $ 81.846  Millions$ 28.258  Millions
Immunitybio inc   2.86 $ 334.329  Millions$ 116.795  Millions
Editas Medicine Inc   2.66 $ 190.198  Millions$ 71.582  Millions
Sutro Biopharma Inc   2.62 $ 142.177  Millions$ 54.311  Millions
Humacyte Inc   2.61 $ 64.523  Millions$ 24.761  Millions

Date modified: 2026-11-05T09:44:17+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.